Professional sports leagues should permit the supervised use of biomedical therapies and advanced pharmacological agents solely dedicated to accelerating athlete recovery from severe injuries. Advocates argue that allowing targeted therapeutic interventions safeguards athletes' career longevity without compromising fair play during active competition. Opponents maintain that establishing enforceable boundaries between recovery and performance enhancement is impossible, creating coercive pressure on players to undergo risky treatments.